Next-Generation Gene Therapies and AAV Products

Through the acquisition of Spark therapeutics in 2019, Roche propelled itself into gene therapy space and hasn’t looked back. Reporting from the December 2023 Cell & Gene Therapy Manufacturing & Commercialization Europe conference in Ireland, this eBook addresses the production of next-generation adenoassociated virus (AAV)–based products. Specifically, the Swiss biopharmaceutical giant hopes to break through the manufacturing limitations that have limited the reach of such lifesaving treatments. Roche wants to create a range of gene therapies that can treat large patient populations at affordable prices. BioProcess Insider also brings you the latest trends in AAV-based gene therapy news.

Fill out the form below to read the full eBook now.